We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals

55 hedge funds and large institutions have $92.1M invested in Amphastar Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

22% more funds holding

Funds holding: 4555 (+10)

9% more capital invested

Capital invested by funds: $84.4M → $92.1M (+$7.77M)

Holders
55
Holders Change
+10
Holders Change %
+22.22%
% of All Funds
1.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
20
Reduced
10
Closed
5
Calls
Puts
Net Calls
Net Calls Change

AMPH Hedge Fund Activity: Q4 2014 in Review

55 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2014, worth a combined $92.1M — up 9.2% from $84.4M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new AMPH positions and 5 closed out — a net gain of 12 holders — while 20 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $5.98M. The largest seller was Federated Hermes, cutting an estimated $4.61M.

  • 55 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2014, up from 45 in Q3 2014.
  • Funds reported $92.1M of Amphastar Pharmaceuticals stock for Q4 2014, up 9.2% quarter-over-quarter.
  • 17 funds opened new Amphastar Pharmaceuticals positions in Q4 2014 and 5 closed out, a net change of +12 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $5.98M added.
  • The largest Amphastar Pharmaceuticals seller in Q4 2014 was Federated Hermes, an estimated $4.61M sold.

Based on aggregated 13F filings for Q4 2014.